Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

C4C

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

Threat of medical device hacking is ‘growing concern’

FDA issues new cybersecurity guidance to help minimise risks

Novartis sets sights on connected inhaler

Plans 2019 launch for Qualcomm-partnered device

- PMLiVE

Novo Nordisk files improved haemophilia B therapy in EU

Nonacog beta pegol is due to be submitted to US regulators in the next few months

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

UCB trials wearable sensor for Parkinson’s

Its medical device combines with a mobile app to measure motor symptom patterns

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

- PMLiVE

iPhone app helps diagnose cardiac arrhythmias

iRhythmTechnologies launches myZIO app

- PMLiVE

PMEA 2015 win for Novo’s Changing Diabetes in Children

Company wins the EY Award for SociallyResponsible Initiatives

- PMLiVE

ResearchKit picked for autism, epilepsy and melanoma studies

Continues Apple's exploration of its iPhone software as amedical research tool

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links